Drugs / Xcellerated T Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00081783 | Mar 2004 → ? | non-Hodgkin lymphoma | Xcyte Therapies | Unknown | No outcome recorded |
| Phase 2 | NCT00078065 | Nov 2003 → Jun 2004 | plasma cell myeloma | Xcyte Therapies | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xcellerated T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00078065 ↗ |
| Known as | Xcellerated T CellsTM | “This randomized Phase II clinical study is designed to examine the safety and efficacy of Xcellerated T CellsTM, an activated, autologous T cell product, in subjects with...” NCT00078065 ↗1“Patients will receive Xcellerated T CellsTM, an ex vivo activated and expanded autologous T cell product” NCT00081783 ↗ |
| Modality | Cell therapy | “an activated, autologous T cell product” NCT00078065 ↗ |